Full text PDF - International Policy Network

Sources 291
4 The diseases of poverty and the 10/90 gap
Attaran, A., Barnes, K., Curtis, C., d’Alessandro, U., Fanello, C., Galinski, M., Kokwaro,
G., Looareesuwan, S., Makanga, M., Mutabingwa, T., (2004), “WHO, the Global
Fund, and medical malpractice in malaria treatment,” The Lancet, 363:9404, pp
237–240.
Barat, L., Palmer, N., Basu, S., Worrall, E., Hanson, K., Mills, A., (2003), “Do Malaria
Control Interventions Reach the Poor?: A view Through the Equity Lens,” Disease
Control Priorities Project, Bethesda: National Institutes of Health.
Black, RE., Where and why are 10 million children dying every year? The Lancet 2003;
361: 2226–34
Bruce, N., Perez-Padilla, R. & Albalak, R., (2002), “The health effects of indoor air
pollution exposure in developing countries”, Geneva: World Health
Organization.
Carrin, G., (2002), “Social Health Insurance in developing countries: a continuing
challenge,” International Social Security Review, Vol. 55.
Chima, R., Goodman, C. & Mills, A., (2003), “The economic impact of malaria in
Africa: a critical review of the evidence,” Health Policy, 63(1): 17–36
Deolalikar, A., (1995), “Government Health Spending in Indonesia: Impact on
Children in Different Economic Groups.” In Public Spending and the Poor: Theory
and Evidence, eds. Van de Walle, D., & Nead, K., Baltimore: John Hopkins
University Press.
Department of Health and Human Services, United States, (2002), “Report to the
President: Prescription drug coverage, spending, utilization, and prices”, April
2002.
de Soto, H., (2001), The Mystery of Capital, London: Bantam Books.
Fenwick, A, (2006), “Waterborne Infectious Diseases – Could They Be Consigned to
History?” Science, 313:5790, pp 1077 – 1081
Filmer, D. & Pritchett, L., (1999), “The Impact of public spending on health: does
money matter?” World Bank
Filmer, D., Hammer, J., Pritchett, L., (2000), “Weak links in the chain: a diagnosis of
health policy in poor countries,” World Bank Research Observer, 15(2): 199–224.
Jones, G., & Stetekee R., (2004), How many child deaths can we prevent this year? The
Lancet, vol 362, 5 July 2004
Kumarasamy, N., (2004), “Generic antiretroviral drugs – will they be the answer to
HIV in the developing world?” The Lancet, vol 364.
Levison, L. & Laing, R., (2003), “The hidden costs of essential medicines,” WHO
essential drugs monitor, Issue 33.
Levison, L., (2003), “Policy and programming options for reducing the procurement
costs of essential medicines in developing countries”, concentration paper:
Boston University School of Public Health.
Love J., Hubbard T., (2003) “An agenda for research and development,” Meeting on
the role of generics and local industry in attaining the Millennium Development
Goals in pharmaceuticals and vaccines. World Bank: Washington DC, June 2003
Monath, T., (2005), “Yellow Fever Vaccine,” Expert Review of Vaccines, 4(4):553–74
Medecins Sans Frontiers & Drugs for Neglected Diseases Working Group, (2001),
“Fatal Imbalance: The Crisis in Research and Development for Drugs for